All Stories

  1. Predicting Alzheimer’s Disease Phenotypes With Aging Clocks: An Exploratory Analysis
  2. The influence of metformin treatment on the circulating proteome
  3. Bayesian network imputation methods applied to multi-omics data identify putative causal relationships in a type 2 diabetes dataset containing incomplete data: An IMI DIRECT Study
  4. The dynamics of the gut microbiota in prediabetes during a four-year follow-up among European patients—an IMI-DIRECT prospective study
  5. A Biological-Systems-Based Analyses Using Proteomic and Metabolic Network Inference Reveals Mechanistic Insights into Hepatic Lipid Accumulation: An IMI-DIRECT Study
  6. Increased activity of Piezo1 channel in red blood cells is associated with Alzheimer's disease‐related dementia
  7. Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
  8. Effect of ventricular volume on cerebrospinal fluid Alzheimer's disease biomarkers in patients with idiopathic normal pressure hydrocephalus
  9. The L-type amino acid transporter 1 enhances drug delivery to the mouse pancreatic beta cell line (MIN6)
  10. Role of human plasma metabolites in prediabetes and type 2 diabetes from the IMI-DIRECT study
  11. TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer’s disease
  12. Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementia
  13. The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study
  14. TWINGEN – protocol for an observational clinical biobank recall and biomarker study to identify individuals with high risk of Alzheimer’s disease
  15. Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits
  16. A FinnGen pilot clinical recall study for Alzheimer’s disease
  17. Cerebrospinal Fluid Diagnostics of Alzheimer’s Disease in Patients with Idiopathic Normal Pressure Hydrocephalus
  18. Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus
  19. Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models
  20. Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals
  21. Author Correction: Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models
  22. A FinnGen pilot clinical recall study for Alzheimer’s disease
  23. Concordance of Alzheimer’s Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus
  24. Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models
  25. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
  26. Protective Alzheimer’s disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models
  27. Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype
  28. Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study
  29. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
  30. Inferring causal pathways between metabolic processes and liver fat accumulation: an IMI DIRECT study
  31. Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study
  32. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance
  33. Genetic analysis of blood molecular phenotypes reveals regulatory networks affecting complex traits: a DIRECT study
  34. Oxygen-18 and carbon-13 isotopes in eCO2 and erythrocytes carbonic anhydrase activity of Finnish prediabetic population
  35. Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
  36. Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study
  37. Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study
  38. Correction to: The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study
  39. A reference map of potential determinants for the human serum metabolome
  40. Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study
  41. Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts
  42. Impact of structurally diverse BET inhibitors on SIRT1
  43. Predicting and elucidating the etiology of fatty liver disease using a machine learning-based approach: an IMI DIRECT study
  44. The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study
  45. A scaffold replacement approach towards new sirtuin 2 inhibitors
  46. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration
  47. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium
  48. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study
  49. Strigolactone GR24 upregulates target genes of the cytoprotective transcription factor Nrf2 in skeletal muscle
  50. Strigolactone GR24 upregulates Nrf2 target genes and may protect against oxidative stress in skeletal muscle
  51. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake
  52. Strigolactone GR24 and pinosylvin attenuate adipogenesis and inflammation of white adipocytes
  53. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: an overview of the data from the epidemiological studies within the IMI DIRECT Consortium
  54. Suppressed heat shock protein response in the kidney of exercise-trained diabetic rats
  55. Plant-derived compounds strigolactone GR24 and pinosylvin activate SIRT1 and enhance glucose uptake in rat skeletal muscle cells
  56. Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation
  57. Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists
  58. N-Acylethanolamines Bind to SIRT6
  59. Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells
  60. Transcriptomic Analysis of Human Primary Bronchial Epithelial Cells after Chloropicrin Treatment
  61. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses
  62. Virtual screening approach of sirtuin inhibitors results in two new scaffolds
  63. Chroman-4-one- and Chromone-Based Sirtuin 2 Inhibitors with Antiproliferative Properties in Cancer Cells
  64. Studying SIRT6 regulation using H3K56 based substrate and small molecules
  65. AROS has a context-dependent effect on SIRT1
  66. Natural thermal adaptation increases heat shock protein levels and decreases oxidative stress
  67. Screen of Pseudopeptidic Inhibitors of Human Sirtuins 1–3: Two Lead Compounds with Antiproliferative Effects in Cancer Cells
  68. Somatostatin receptor 5 is palmitoylated by the interacting ZDHHC5 palmitoyltransferase
  69. Treatments with sodium selenate or doxycycline offset diabetes-induced perturbations of thioredoxin-1 levels and antioxidant capacity
  70. An inter-laboratory validation of methods of lipid peroxidation measurement in UVA-treated human plasma samples
  71. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation
  72. The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor
  73. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2receptor
  74. Important amino acids for the function of the human MT1 melatonin receptor
  75. Mutagenesis of Human Mel1aMelatonin Receptor Expressed in Yeast Reveals Domains Important for Receptor Function
  76. TCDD alters melatonin metabolism in fish hepatocytes
  77. Melatonin receptor genes
  78. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor
  79. Mechanism by which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduces circulating melatonin levels in the rat
  80. Cholinergic signaling in the rat pineal gland